Treatment of multiple myeloma Sanofi CD38 antibody combination therapy reaches phase 3 clinical end

MM is a blood cancer caused by plasma cell cancer in the bone marrowAbnormal plasma cells accumulate in the bone marrow and produce tumors in multiple bones in the bodyNot only do these cells not function properly, they also cause the bone marrow to fail to produce healthy blood cellsCancerous plasma cells affect the production of normal blood cells, leading to a decline in blood cell index, bone damage and kidney damageAlthough many advances have been made in the treatment of MM in recent years, most MM patients still face relapse or drug resistance problems, threatening their livesIsatuximab is a monoclonal antibody that targets CD38 receptors on the surface of plasma cells and can trigger a variety of different mechanisms of action to promote apoptosis and regulate immune responsesIn March, the FDA announced that it had approved the use of isatuximab in conjunction with pomalidomide and dexamethasone to treat adult patients with multiple myelomaThese patients received at least two pre-treatments, including lenalidomide and protease inhibitorsstudy called IKEMA is a randomized, multicenter, open-label Phase 3 clinical trial designed to evaluate the efficacy and safety of adding isatuximab to the current MM standard treatment regimenAll patients involved in the trial were treated with 1 to 3 pre-treatmentsThe main endpoint of the experiment was the progression-free survivalSecondary endpoints include indicators such as total mitigation rate, total lifetime, and safetyThe positive results of the study will be presented at future academic conferences" results from this Phase 3 clinical trial show that when isatuximab is added to the standard treatment drugs carfilzomib and dexamethasone, the patient's risk of disease progression or death is significantly reduced," said DrJohn Reed, Sanofi's Global Head of Research and Developmentaccording to the latest announcement on the website of the Drug Review Center (CDE) of The State Drug Administration of China, the isatuximab injection has submitted two new clinical trial applications in ChinaSanofi is conducting two clinical trials in patients with multiple myeloma, one of which is a randomized, open-label, international multi-center phase 3 clinical program, designed to compare isatuximab combined with boboti, rhamine and dexamethasone, with bobutyzomi, Compared to dexamethasone, the beneficiaries of the new diagnosis of multiple myeloma and not suitable for transplantation have no progressive survival, and the other is a Phase 1 clinical study designed to assess the pharmacokinetics, safety and initial efficacy of isatuximab for recurrent/refractory multiple myeloma patients in China image source: CDE official website Source: sarclisa® (isatuximab) Phase 3 IKEMA trial siprimary primary early in patients with relapsed myeloma Retrieved 2020-05-12, https:// original title: Sanofi CD38 antibody combination therapy reaches Phase 3 clinical end, has submitted a clinical trial application in China